|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0010583,
umls-concept:C0013089,
umls-concept:C0015133,
umls-concept:C0030705,
umls-concept:C0038250,
umls-concept:C0183683,
umls-concept:C0278689,
umls-concept:C0282460,
umls-concept:C0344211,
umls-concept:C0348016,
umls-concept:C0439859,
umls-concept:C1171411,
umls-concept:C1317973,
umls-concept:C1521721,
umls-concept:C1609982,
umls-concept:C2003874
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2002-1-8
|
|
pubmed:abstractText |
This study was performed in order to evaluate the toxicities, progression-free and overall survival of patients with responsive residual or recurrent ovarian cancer treated with high-dose chemotherapy. Twenty-seven patients were treated. Doxorubicin, 165 mg/m(2) over 96 h (days -12 to -8), etoposide 700 mg/m(2) every day x3 (days -6 to -4), and cyclophosphamide 4.2 g/m(2) on d -3 was followed by stem cells and granulocyte colony-stimulating factor. The median days of granulocyte count <500/microl was 14 (range 10-42) and platelets <20,000/microl was 13 (range 2-80). Median numbers of red cell and platelet transfusions were 15 (5-16) and 14 (4-103). Toxicity included mucositis requiring narcotic analgesia in all patients. Asymptomatic decreases in ejection fraction to values <50% were observed in four patients. No clinical congestive heart failure was observed. One death due to sepsis was observed. Median progression-free survival is 7.5 months (1.0-56 months); five patients remain alive, two of whom remain progression-free at 19.5 and 24.5 months post transplant. Median overall survival is 14.0 months (1-68 months). We conclude that high-dose anthracyclines may be safely administered to ovarian cancer patients. The short overall and progression-free survivals observed in our population suggest that this combination is not optimal.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0268-3369
|
|
pubmed:author |
pubmed-author:AlvarnasJJ,
pubmed-author:ChowWW,
pubmed-author:DoroshowJ HJH,
pubmed-author:FormanSS,
pubmed-author:HamasakiVV,
pubmed-author:LeoneNN,
pubmed-author:LongmateJJ,
pubmed-author:MargolisPP,
pubmed-author:McGonigleKK,
pubmed-author:McNamaraMM,
pubmed-author:MorganR JRJ,
pubmed-author:RaschkeDD,
pubmed-author:SchriberJJ,
pubmed-author:ShibataSS,
pubmed-author:SomloGG,
pubmed-author:VasilevSS,
pubmed-author:YenYY
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
859-63
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:11781646-Adult,
pubmed-meshheading:11781646-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11781646-CA-125 Antigen,
pubmed-meshheading:11781646-Carcinoma,
pubmed-meshheading:11781646-Combined Modality Therapy,
pubmed-meshheading:11781646-Cyclophosphamide,
pubmed-meshheading:11781646-Disease-Free Survival,
pubmed-meshheading:11781646-Doxorubicin,
pubmed-meshheading:11781646-Etoposide,
pubmed-meshheading:11781646-Female,
pubmed-meshheading:11781646-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:11781646-Humans,
pubmed-meshheading:11781646-Male,
pubmed-meshheading:11781646-Middle Aged,
pubmed-meshheading:11781646-Neoplasm Proteins,
pubmed-meshheading:11781646-Ovarian Neoplasms,
pubmed-meshheading:11781646-Ovariectomy,
pubmed-meshheading:11781646-Survival Analysis,
pubmed-meshheading:11781646-Transplantation, Autologous,
pubmed-meshheading:11781646-Treatment Failure,
pubmed-meshheading:11781646-Treatment Outcome,
pubmed-meshheading:11781646-Tumor Markers, Biological
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer.
|
|
pubmed:affiliation |
Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Clinical Trial, Phase II
|
